Share development opportunities with China and better protect the health of the Chinese public
Thomas Triomphe, Executive Vice President of Sanofi Vaccine Global Division of people's Daily online-International Channel. Thomas Triomphe, Executive……
quality health products and services
the health awareness of the Chinese public has also changed significantly
and the positive health concept of "prevention first" has become more and more deeply rooted in the hearts of the people. through a healthy lifestyle
vaccination and other means
we have always been optimistic about the vitality and potential of the Chinese market. For example
by 2022
our children's joint vaccine products have cumulatively protected more than 12 million Chinese babies on Chinese mainland.In the future
Sanofi will continue to implement the localization operation strategy and increase investment in China
and continue to introduce more innovative products and innovative preventive measures to better meet the Chinese public's yearning for a better life. At the Fifth Expo in 2022
Sanofi Vaccine brought Beyfortus (nirsevimab)
the world's first and only respiratory syncytial virus (RSV) that can be widely used in newborns and infants
just hours after the product was first approved in the European Union. At present
it has obtained the "breakthrough therapeutic drug procedure" granted by the Drug Evaluation Center of China's State Drug Administration
and we look forward to seeing this product with the Chinese public as soon as possible in the future.In addition
as an important innovation center in the world
China has made great achievements in artificial intelligence
5G
biotechnology and other fields. We also hope that Chinese wisdom can bring more innovative solutions to the world. Therefore
we have established the Great Bay area International Vaccine Innovation Center in Shenzhen